MNOV MEDICINOVA INC

CIK 0001226616 7 ready 8-Ks latest February 20, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 7

Latest filing February 20, 2026, 6:59 PM ET

Top materiality 0.65

Event mix other_material ×3 · other ×2 · earnings ×1

Sentiment 0 pos · 1 neg · 6 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for MNOV

Highest-materiality recent filing

MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M

February 20, 2026, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.
Operating loss widened to $13.3M from $12.7M; net sales (collaboration revenue) totaled $0.41M.

Read filing →

February 20, 2026, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M

Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.
December 30, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

MediciNova enters equity distribution agreement for up to $50M at-the-market offering

Agreement with Lucid Capital Markets as sales agent for at-the-market sales of common stock.

Executive changes

Departed

Geoffrey O'Brien

Vice President

MNOV · MEDICINOVA INC

Effective: 2024-04-02
Filed: April 1, 2024, 7:59 PM ET

On March 26, 2024, Geoffrey O’Brien informed MediciNova, Inc. (the “Company”) of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024.

Earnings & guidance

2025-FY EPS reported -$0.24 filing →

Materiality & sentiment trend

Max materiality 0.65 · Median 0.40 · Most common event other_material

0 positive 1 negative 6 neutral

source · MNOV on sec.gov